NASDAQ : SNOA
Sonoma Pharmaceuticals, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 1.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.27M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.12M |
| Enterprise Value | 524,136 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 4.79M |
| Shares Outstanding | 4.79M |
| Shares Change (YoY) | +55.39% |
| Shares Change (QoQ) | +121.67% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 2.31% |
| Float | 4.77M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.24 |
| Forward PS | 0.32 |
| PB Ratio | 0.80 |
| P/TBV Ratio | 0.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.99 |
| Quick Ratio | 1.56 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -42.52% |
| Return on Assets (ROA) | -5.37% |
| Return on Invested Capital (ROIC) | -14.57% |
| Return on Capital Employed (ROCE) | -11.11% |
| Weighted Average Cost of Capital (WACC) | 10.01% |
| Revenue Per Employee | $2.19M |
| Profits Per Employee | -$226,400 |
| Employee Count | 10 |
| Asset Turnover | 1.34 |
| Inventory Turnover | 3.53 |
Taxes
| Measure | Value |
|---|
| Income Tax | -243,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -72.50% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.70 |
| Relative Strength Index (RSI) | 39.89 |
| Average Volume (20 Days) | 41,235 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 108,814 |
| Short Previous Month | 164,505 |
| Short % of Shares Out | 2.27% |
| Short % of Float | 2.28% |
| Short Ratio (days to cover) | 2.24 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 21.92M |
| Gross Profit | 8.53M |
| Operating Income | -1.41M |
| Pretax Income | -2.51M |
| Net Income | -2.26M |
| EBITDA | -1.27M |
| EBIT | -1.41M |
| Loss Per Share | -$1.01 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.34M |
| Total Debt | 739,000 |
| Net Cash | 4.60M |
| Net Cash Per Share | $0.96 |
| Equity (Book Value) | 6.59M |
| Book Value Per Share | 1.38 |
| Working Capital | 10.82M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.57M |
| Capital Expenditures | -88,000 |
| Depreciation & Amortization | 135,000 |
| Net Borrowing | 5,000 |
| Free Cash Flow | -2.66M |
| FCF Per Share | -$0.55 |
Margins
| Measure | Value |
|---|
| Gross Margin | 38.91% |
| Operating Margin | -6.41% |
| Pretax Margin | -11.44% |
| Profit Margin | -10.33% |
| EBITDA Margin | -5.80% |
| EBIT Margin | -6.41% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -55.39% |
| Shareholder Yield | -55.39% |
| Earnings Yield | -94.67% |
| FCF Yield | -50.41% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -13.61 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |